KR101392204B1 - Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases - Google Patents
Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases Download PDFInfo
- Publication number
- KR101392204B1 KR101392204B1 KR1020120019860A KR20120019860A KR101392204B1 KR 101392204 B1 KR101392204 B1 KR 101392204B1 KR 1020120019860 A KR1020120019860 A KR 1020120019860A KR 20120019860 A KR20120019860 A KR 20120019860A KR 101392204 B1 KR101392204 B1 KR 101392204B1
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- green tea
- dermis
- extract
- herbal
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 201000011528 vascular disease Diseases 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 title claims description 63
- 241000207199 Citrus Species 0.000 title description 4
- 235000020971 citrus fruits Nutrition 0.000 title description 4
- 210000004207 Dermis Anatomy 0.000 claims abstract description 55
- 244000269722 Thea sinensis Species 0.000 claims abstract description 51
- 235000009569 green tea Nutrition 0.000 claims abstract description 49
- 240000001810 Angelica gigas Species 0.000 claims abstract description 39
- 235000018865 Angelica gigas Nutrition 0.000 claims abstract description 39
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 11
- 208000003067 Myocardial Ischemia Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010002383 Angina pectoris Diseases 0.000 claims abstract description 10
- 208000010125 Myocardial Infarction Diseases 0.000 claims abstract description 10
- 208000006011 Stroke Diseases 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 241000411851 herbal medicine Species 0.000 claims description 25
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 18
- 230000036541 health Effects 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229940079593 drugs Drugs 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 claims 4
- 206010061256 Ischaemic stroke Diseases 0.000 claims 4
- 241000125175 Angelica Species 0.000 claims 3
- 230000002730 additional Effects 0.000 claims 2
- 206010057190 Respiratory tract infection Diseases 0.000 claims 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 206010008118 Cerebral infarction Diseases 0.000 abstract description 5
- 206010008111 Cerebral haemorrhage Diseases 0.000 abstract description 4
- 201000001320 atherosclerosis Diseases 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 44
- 230000000694 effects Effects 0.000 description 21
- 240000002045 Guettarda speciosa Species 0.000 description 10
- 210000001772 Blood Platelets Anatomy 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 210000004369 Blood Anatomy 0.000 description 7
- 235000002791 Panax Nutrition 0.000 description 7
- 241000208343 Panax Species 0.000 description 7
- 240000004371 Panax ginseng Species 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 235000020688 green tea extract Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000003078 antioxidant Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 240000001992 Angelica archangelica Species 0.000 description 5
- 229940094952 Green Tea Extract Drugs 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 210000004623 Platelet-Rich Plasma Anatomy 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 235000005035 ginseng Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000245665 Taraxacum Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229960005188 collagen Drugs 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 235000009242 dandelion Nutrition 0.000 description 4
- 235000014079 dandelion Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- -1 styryl poly Titanium Chemical compound 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 3
- 210000001367 Arteries Anatomy 0.000 description 3
- 206010007554 Cardiac failure Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010019280 Heart failure Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003110 anti-inflammatory Effects 0.000 description 3
- 230000000702 anti-platelet Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229930016253 catechin Natural products 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- DSNBHJFQCNUKMA-SCKDECHMSA-M thromboxane A2(1-) Chemical compound [O-]C(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-M 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 150000003700 vitamin C derivatives Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- 241000092897 Angelica japonica Species 0.000 description 2
- 229940114079 Arachidonic Acid Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001736 Capillaries Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N Catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 229940100626 Catechin Drugs 0.000 description 2
- 229950001002 Cianidanol Drugs 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 241000555678 Citrus unshiu Species 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N Coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 210000004195 Gingiva Anatomy 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside Rg2 Natural products O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N Ginsenoside Rg3 Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 2
- RAQNTCRNSXYLAH-RFCGZQMISA-N Ginsenoside Rh1 Natural products O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229940025878 Hesperidin Drugs 0.000 description 2
- QUQPHWDTPGMPEX-YEDPJISVSA-N Hesperidin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 QUQPHWDTPGMPEX-YEDPJISVSA-N 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 210000003497 Sciatic Nerve Anatomy 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 240000001132 Stevia rebaudiana Species 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003178 anti-diabetic Effects 0.000 description 2
- 230000000845 anti-microbial Effects 0.000 description 2
- 230000000259 anti-tumor Effects 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000011778 trisodium citrate Substances 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- PVLHOJXLNBFHDX-XHJPDDKBSA-N (3S,5R,8R,9R,10R,12R,13R,14R,17S)-4,4,8,10,14-pentamethyl-17-[(2R)-2,6,6-trimethyloxan-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,12-diol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3β-hydroxy-Olean-12-en-28-oic acid Chemical group C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004958 Brain cells Anatomy 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 241001140724 Citrus tachibana Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N Dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N Epicatechin gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 230000036081 Excretion rate Effects 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229940089161 Ginsenoside Drugs 0.000 description 1
- YURJSTAIMNSZAE-KFVUSEMXSA-N Ginsenoside Rg1 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 YURJSTAIMNSZAE-KFVUSEMXSA-N 0.000 description 1
- LPLVUJXQOOQHMX-MYOOOWEVSA-N Glycyrrhizic acid Natural products O=C(O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1 LPLVUJXQOOQHMX-MYOOOWEVSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 208000002287 Hemorrhoids Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- DFPMSGMNTNDNHN-OHXUDFEXSA-N Naringin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(O)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 DFPMSGMNTNDNHN-OHXUDFEXSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N Neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-NRRCNVALSA-N Neohesperidin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3cc(O)c(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 ARGKVCXINMKCAZ-NRRCNVALSA-N 0.000 description 1
- ZIKZPLSIAVHITA-UHFFFAOYSA-N Nomilinic acid Chemical compound CC(=O)OC(CC(O)=O)C1(C)C(C(C)(C)O)CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 ZIKZPLSIAVHITA-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241001527087 Panax vietnamensis Species 0.000 description 1
- 235000017726 Panax vietnamensis Nutrition 0.000 description 1
- 241000180664 Panax wangianus Species 0.000 description 1
- 235000003138 Panax wangianus Nutrition 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N Pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000001322 Periplasm Anatomy 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N Rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229940081967 Rutin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N Stevioside A3 Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 240000008529 Triticum aestivum Species 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- AGABNGOXUSXQDD-XKGFZTIGSA-N [(3S)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] (Z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C(\C)=C/C)C(C)(C)OC1=C2 AGABNGOXUSXQDD-XKGFZTIGSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000003266 anti-allergic Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000003276 anti-hypertensive Effects 0.000 description 1
- 230000002790 anti-mutagenic Effects 0.000 description 1
- 230000002965 anti-thrombogenic Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005097 cold rolling Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- BGXFQDFSVDZUIW-LBPRGKRZSA-N decursinol Chemical compound O1C(=O)C=CC2=C1C=C1OC(C)(C)[C@@H](O)CC1=C2 BGXFQDFSVDZUIW-LBPRGKRZSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229930003335 epicatechin Natural products 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229930003935 flavonoids Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 200000000002 platelet activation Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229930002161 purine alkaloids Natural products 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002876 rutin Natural products 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000037327 stress response Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001732 thrombotic Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000001256 tonic Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 238000005429 turbidity Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
본 발명은 홍삼, 당귀, 진피 및 녹차를 함유하는 혈관 질환의 예방 또는 치료용 조성물에 관한 것으로, 상기 조성물은 혈소판 응집억제 효과가 뛰어나 동맥경화증, 고혈압, 협심증, 심근경색, 허혈성 심장질환, 심부전, 경혈관 동맥 성형술 후 발생하는 합병증, 뇌경색, 뇌출혈, 및, 뇌졸중 등을 비롯한 혈관 질환의 치료제로서 유용하게 사용될 수 있다.The present invention relates to a composition for preventing or treating vascular diseases containing red ginseng, Angelica gigas, dermis, and green tea. The composition is excellent in a platelet aggregation inhibiting effect and is useful as a therapeutic agent for atherosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, And may be useful as a therapeutic agent for vascular diseases including cerebral infarction, cerebral infarction, cerebral hemorrhage, stroke,
Description
본 발명은 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 함유하는 혈관 질환의 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating vascular diseases containing herbal extracts of red ginseng, Angelica gigas, dermis and green tea.
현대 사회에서 혈관 질환은 심각한 사회적 문제로 대두되고 있다. 2010년 통계청에서 발표한 사망원인 통계를 보면, 고혈압성 질환, 허혈성 심장 질환, 뇌혈관 질환을 포함한 혈관 질환은 우리나라 사망원인의 2위로서, 악성 종양 다음으로 높은 순위를 차지하고 있으며, 남성은 55세 이상, 여성은 65세 이상에서 혈관 질환의 사망률이 크게 증가한다. 특히 동맥경화증과 관련된 위험인자는 연령, 성별, 고혈압, 고지혈증, 당뇨병, 흡연, 운동 부족과 비만이다. 상기 혈관 질환으로는 동맥경화증, 고혈압, 협심증, 심근경색, 허혈성 심장질환, 심부전, 경혈관 동맥 성형술 후 발생하는 합병증, 뇌경색, 뇌출혈, 및, 뇌졸중 등이 있다. 혈관 질환 환자들은 이를 치료하기 위해 지속적인 약물을 투여받지만 현대 의학에서 완치가 되기는 쉽지 않다. 또 약물을 오래 투여하다가 보면 그에 대한 부작용도 크다. In modern society, vascular disease is becoming a serious social problem. According to the statistics released by the National Statistical Office in 2010, vascular diseases including hypertensive diseases, ischemic heart diseases and cerebrovascular diseases are the second leading cause of death in Korea, followed by malignant tumors, Or more, the mortality rate of vascular disease is greatly increased in women over 65 years of age. In particular, risk factors associated with atherosclerosis are age, sex, hypertension, hyperlipidemia, diabetes, smoking, lack of exercise and obesity. Examples of the vascular diseases include arteriosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, complications arising after pericardial artery arteriography, cerebral infarction, cerebral hemorrhage, and stroke. Patients with vascular disease receive continuous medication to treat it, but it is not easy to cure it in modern medicine. If you take the medicine for a long time, the side effect is big.
한편, 혈관 질환의 예방 및 치료를 위하여 민간 또는 동의보감 등의 전통의서에 많은 생약이 소개되어 있는데, 그 중에서도 특히 당귀, 진피, 홍삼, 녹차 등은 그 활성이 전통의서 뿐 아니라 현대적인 실험에서도 증명이 되어 있다.On the other hand, for the prevention and treatment of vascular diseases, many herbal medicines are introduced in the traditional books such as the private or Dongbibogam. Among them, Angelica, dandelion, red ginseng, It has been proven.
홍삼(紅衫, red ginseng)은 인삼(人蔘, ginseng)의 뿌리를 쪄서 제조한 붉은 인삼이다. 홍삼의 제조에 이용될 수 있는 인삼은 파낙스(Panax)속에 속하는 다년생 식물로, 고려인삼(Panax ginseng), 화기삼(Panax quinquefolia), 전칠삼(삼칠, Panax notoginseng), 죽절삼(Panax vietnamensis), 파낙스 엘레가티오르(Panax elegatior), 파낙스 완지아누스(Panax wangianus) 또는 파낙스 비핀라티피두스(Panax bipinratifidus), 파낙스 안구스티폴리움(Panax angustifolium) 등이 있다. 홍삼은 사포닌을 많이 함유하고 있는데, 식물계에서 존재하는 대부분의 사포닌은 올레아난(oleanane) 계열이고 홍삼 사포닌은 타 식물계에 거의 존재하지 않는 담마란(dammarane) 계열의 트리테르페노이드(triterpenoid) 사포닌으로서, 홍삼 특유의 사포닌 성분으로는 진세노사이드(ginsenoside) Rh2, Rg2, Rg3, Rg1, Rh1 등이 있다. 사포닌의 일반적인 특징은 물, 알코올에 잘 녹고 지속적으로 거품이 나며 생리적으로 해독작용이 있으며 과량 투여에 독성이 없다고 밝혀져 있다. 특히, 진세노사이드는 중추신경계를 비롯하여 내분비계, 면역계, 대사계 등에 영향을 미쳐 신체조절기능에 다양한 효과를 발휘한다고 알려져 있다. 홍삼은 자양강장작용, 면역증강작용, 혈당강하 등의 약리효과가 있으며, 심박출량과 중심정맥압을 낮춰서 혈관 질환에 탁월한 효과를 갖는다고 한다. 또한, 홍삼의 에탄올 추출물의 감마선 조사를 통한 항암효과 증대(비특허문헌 1), 발효홍삼 분말 급여에 의한 흰쥐의 혈청 지질 농도 및 항산화 활성에 미치는 영향(비특허문헌 2), 정상인에서 홍삼이 스트레스 반응 및 베타-아드레날린 수용체 기능에 미치는 효과(비특허문헌 3) 등에 개시된 바와 같이, 홍삼이 의료용, 기능성 식품 등 여러 분야에서 폭넓게 쓰일 수 있음이 알려져 있다. 이 외에도, 홍삼은 ‘피로회복’, ‘면역력 증진’, ‘혈소판 응집 억제를 통한 혈액 흐름에 도움’, ‘기억력 개선’ 등의 기능성이 인정된 바 있다. Yu 등이 동물의 혈소판에 홍삼 추출물을 처리한 결과, 혈소판 응집 유도 물질(콜라겐, 아라키돈산, 트롬빈 등)에 의해 유도된 혈소판 응집 물질이 용량 의존적으로 억제되되, APTT(activated partial thromboplastin time), PT(prothrombin time)에는 영향이 없는 것을 개시한 바 있으며(비특허문헌 4), Park 등의 연구에서는 홍삼 중 파낙사디올(panaxadiol)계 사포닌이 정상 성인 혈소판에서 트롬빈에 의한 TXA2(thromboxane A2) 생성을 감소시킴을 확인한 바 있다(비특허문헌 5). 신경섭 등은 20~65세의 건강인을 대상으로 하루에 홍삼 농축액 3g을 섭취시킨 사람들에게 이중맹검 연구를 수행한 결과, 혈소판 응집은 유의하게 감소하되, APTT는 유의차가 없었다고 보고한 바 있다(비특허문헌 6). 또한, 홍삼 제품류를 4~5년 동안 장기 섭취한 사람과 섭취하지 않은 사람을 비교한 이정희 등의 연구에서는 장기섭취군의 혈소판 응집 반응이 유의하게 감소하였으며 혈액응고시간이 유의하게 증가함이 보고된 바 있다(비특허문헌 7). Red ginseng (red ginseng) is a red ginseng produced by steaming roots of ginseng (ginseng). Ginseng that can be used for the production of red ginseng is a perennial plant belonging to the genus Panax, ginseng , Panax quinquefolia , and Panax notoginseng , Panax vietnamensis , Panax elegatior , Panax wangianus) or non-Panax pinra typhimurium Douce (Panax bipinratifidus), Panax eye styryl poly Titanium (Panax angustifolium ). Red ginseng contains a large amount of saponin. Most saponin present in the plant is oleanane, and red ginseng saponin is triterpenoid saponin of the dammarane family And ginsenoside Rh2, Rg2, Rg3, Rg1, Rh1 and the like as the saponin component peculiar to red ginseng. The general characteristic of saponin is that it is soluble in water, alcohol, it is consistently bubbling, physiologically detoxifying, and is not toxic to overdose. In particular, ginsenoside has been known to exert various effects on the body control function by affecting the central nervous system, the endocrine system, the immune system, and the metabolic system. Red ginseng has pharmacological effects such as nourishing tonic action, immunity enhancing action, and blood sugar lowering, and has excellent effect on vascular disease by lowering cardiac output and central venous pressure. In addition, the anti-cancer effect of the ethanol extract of red ginseng was enhanced by gamma irradiation (Non-Patent Document 1), the effect of fermented red ginseng powder on the serum lipid concentration and antioxidant activity in rats (Non-Patent Document 2) Reaction and Effects on Beta-adrenergic Receptor Function (Non-Patent Document 3) It is known that red ginseng can be widely used in various fields such as medical and functional foods. In addition, red ginseng has been recognized for its functional properties such as 'restoring fatigue', 'improving immunity', 'helping blood flow through inhibiting platelet aggregation', and 'improving memory'. Yu et al. Treated red ginseng extract on platelets of animals showed that platelet aggregation substances induced by platelet aggregation inducers (collagen, arachidonic acid, thrombin, etc.) were dose-dependently inhibited, but activated partial thromboplastin time (APTT) (non-patent document 4). Park et al. have reported that panaxadiol saponins in red ginseng produce thromboxane A2 (TXA2) by thrombin in normal platelets (Non-Patent Document 5). In a double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, Patent Document 6). In addition, the study by Lee, Jung-Hee, et al., Who compared long-term ingestion of red ginseng products for 4 to 5 years, showed a significant decrease in platelet aggregation response and a significant increase in blood coagulation time (Non-Patent Document 7).
당귀(當歸, Angelicae gigantis Radix)는 참당귀(Angelica gigas Nakai)의 뿌리를 사용한다. 중국에서는 중국당귀(Angelica sinensis (Oliv.) Diels:中國當歸)를 사용하고 일본에서는 왜당귀(Angelica acutiloba (Sieb. & Zuc.) Kitagawa)를 사용한다. 당귀에는 주로 쿠마린(coumarin) 계통의 데커신(decursin), 데커시놀(decursinol), 데커시놀 안젤레이트(decursinol angelate) 등이 함유되어 있다. 데커신과 데커시놀은 진정, 진통, 진경작용, 항종양작용, 뇌세포 보호작용 등이 있으며, 특히 혈소판 응집 억제작용이 있어 혈관 치료에 효과가 있는 것으로 알려져 있다. 한방에서는 당귀가 빈혈증, 부인병, 임산부의 산후 회복에 주로 쓰이며 이외에도 심한 기침, 부스럼 등에 효과가 있다고 알려져 있다. 또한, 당귀는 자궁을 튼튼하게 할 뿐 아니라 생리를 조절하여 어혈 등의 노폐물을 빼내는 역할을 하며 냉증, 혈색 불량 등을 개선시키며, 산전 산후의 회복에 도움이 되고, 피가 부족할 때 보혈작용을 할 뿐만 아니라, 피의 순환을 원활하게 해주고, 혈액 정화작용 및 장의 운동을 활발하게 해주므로 손발이 찬 증상을 개선시킬 수 있다고 한다(비특허문헌 8). 당귀에 관한 연구로는, 당귀 성분을 첨가한 한방 화장품 연구(비특허문헌 9), 당귀가 렛드(rat)의 손상된 좌골신경 재생에 미치는 영향(비특허문헌 10), 당귀 추출물 및 데커신의 피부노화 억제효능에 대한 연구(비특허문헌 11), 캡슐화 당귀 분말이 여성호르몬 변화 및 골다공증에 미치는 영향 연구(비특허문헌 12) 등이 보고된 바 있어, 당귀가 의료 목적 외에도 건강기능성 식품으로도 많은 관심을 받고 있음을 알 수 있다. Angelica (當歸, Angelicae gigantis Radix) Angelica gigas Nakai is (Angelica gigas Nakai) roots are used. In China, Chinese Angelica Sinensis (Oliv.) Diels: 中國 当期) is used in Japan and why Angelica acutiloba (Sieb. & Zuc.) Use Kitagawa). Angelica contains mainly coumarin-based decursin, decursinol, decursinol angelate and the like. Decker Shin and Decker Cynol are known to have sedative, analgesic action, antitumor action, antitumor action, brain cell protective action, and especially anti-platelet aggregation, which is effective for vascular treatment. In one room, Angelicae is used mainly for the recovery of anemia, women's diseases and postpartum of pregnant women. Besides, it is known that it is effective for severe cough and swelling. In addition, it not only strengthens the uterus but also regulates the physiology to remove waste products such as hemorrhoids, improves the poor circulation, improves the color deficiency, helps to recover the prenatal and postnatal blood, In addition, the blood circulation can be smoothly performed, and blood purification and intestinal motions can be actively promoted, thereby improving hand and foot symptoms (Non-Patent Document 8). Studies on Angelica gigas include studies on herbal cosmetics containing Angelica keiskei kana (non-patent document 9), effects on damaged sciatic nerve regeneration of Angelica gigas rat (non-patent document 10), Angelica gigantosa extract and skin aging (Non-patent document 11), studies on the effect of encapsulated Angelica gigasum powder on female hormone changes and osteoporosis (non-patent document 12), etc., .
진피(陳皮, Citrus peel)는 우리나라에서는 운향과의 귤(Citrus unshiu Markovich) 또는 동속 근연식물(산초과 Rutaceae)의 성숙한 과피를 말한다. 일본에서는 귤(Citrus unshiu Markovich)과 병감(Citrus reticulata Blanco:柑)을 진피로, 귤감( Citrus tachibana(Makino) Tanaka:橘柑)을 귤피(橘皮)로 사용하고 있으며 중국에서는 병감(Citrus reticulata Blanco:柑) 및 그 재배변종을 진피로 규정하고 있다. 건조된 귤피에는 플라보노이드(flavonoid) 계열의 헤스페리딘(hesperidin), 루틴(rutin), 나린진(naringin), 네오헤스페리딘(neohesperidin) 등이 있으며 리모노이드(limonoid) 계열의 노밀리닉산(nomilinic acid) 등이 있으며, 특히, 헤스페리딘이 4.0% 이상 함유되어 있다. 이 외에도, 비타민 B1, 비타민 C, 칼슘, 철분, 식이섬유 등이 다랑 함유되어 있다. 이 중에서도, 상기 비타민 C는 신진대사를 원활하게 하여 체온이 내려가는 것을 막아주고 겨울철 감기를 예방하는 효과를 가져오며, 피부와 점막을 튼튼하게 하는 역할을 하는 것으로 알려져 있다. 진피의 약효로는 건위, 구풍작용, 항알러지 작용 등이 있으나 가장 주된 효과는 모세관혈관 강화작용을 들 수 있으며, 이로 인해 진피를 고혈압, 뇌출혈, 뇌경색 등의 여러 혈관 질환의 예방 및 치료에 이용할 수 있다. 한편, 진피에 대해서는, 진피의 항톡소포자충 효과(비특허문헌 13), 제주산 진피를 이용한 단일 침출차의 가공 특성 및 항산화성(비특허문헌 14), 진피의 항염 효과(비특허문헌 15)에 관한 연구 등이 있으며, 주로 진피의 항산화 효과에 초점을 맞춰 연구가 되어 왔다. The dermis (Citrus peel) in Korea is the citrus ( Citrus unshiu Markovich) or the mature periplasm of an in situ relative plant ( Rutaceae excess). In Japan, citrus unshiu Markovich) and byeonggam (Citrus reticulata Blanco: the柑) into the dermis, gyulgam (Citrus tachibana (Makino) Tanaka: 橘 柑) is used as a citrus peel (橘花) in China and the disease ( Citrus reticulata Blanco: 柑) and its cultivar variant as dermis. Dried peaches are flavonoids such as hesperidin, rutin, naringin, neohesperidin and the like, and limonoid-based nomilinic acid and the like , In particular, 4.0% or more of hesperidin. In addition, it contains vitamin B1, vitamin C, calcium, iron, dietary fiber and so on. Among them, the vitamin C is known to play a role of strengthening the skin and the mucous membrane by preventing the body temperature from lowering by smoothly metabolizing, preventing the cold in winter, and the like. The main effects of the dermis include arthropods, windbreaks, and anti-allergic effects, but the main effect is capillary vascular strengthening, which can be used to prevent and treat various vascular diseases such as hypertension, cerebral hemorrhage, and cerebral infarction have. On the other hand, regarding the dermis, the processing characteristics and antioxidant properties of a single leach using a dermis (non-patent document 13), dermis anti-inflammatory effect (non-patent document 15) And research on the antioxidant effect of dermis.
녹차(綠茶, green tea)는 차나무로부터 채취할 수 있는데 차나무는 인도 앗샴 지역이 원산지이다. 녹차의 성분으로는 페놀 화합물(phenolic compound)인 카테친(catechin), 에피카테친(epicatechin), 에피카테친 갈레이트(epicatechin gallate) 등이 있고 퓨린 알칼로이드(purine alkaloid)인 카페인(caffeine), 잔틴(xanthine) 등이 있다. 카테친은 특히 활성산소를 없애는데 뛰어난 효과가 있으며, 비타민 C의 40~100배의 항산화력을 가지고 있으며, 항염증, 항돌연변이, 항암작용 등이 있고 항고혈압작용, 모세관혈관 강화작용, 항혈전 작용이 있어 심혈관계 치료 및 예방에 도움이 된다고 알려진 기능성 물질이다. 녹차에 대한 연구로는, 항-당뇨 효과에 대한 메타회귀분석(비특허문헌 16), 녹차추출물로부터 항균물질의 분리 및 구조 동정(비특허문헌 17), 열수 녹차추출물이 생쥐의 체중 및 부고환 지방축적 조절에 미치는 영향(비특허문헌 18) 등의 연구가 진행된 바 있다. Green tea can be harvested from the tea plantation. The tea plantation originates in the region of India. The components of green tea are phenolic compounds such as catechin, epicatechin, epicatechin gallate, and purine alkaloids such as caffeine, xanthine, . Catechin has excellent antioxidant activity against vitamin C, anti-inflammation, antimutagenic and anticancer effects, anti-hypertensive effect, capillary vascular strengthening effect, antithrombotic effect It is a functional substance known to be helpful for cardiovascular treatment and prevention. Studies on green tea include meta-regression analysis of anti-diabetic effect (non-patent document 16), isolation and structure identification of antimicrobial substance from green tea extract (non-patent document 17), weight loss and epididymal fat And the influence on the accumulation control (Non-Patent Document 18).
한편, 상기 생약들에 대해서, 진피와 홍삼 등이 혼합된 생약 조성물의 메탄올 추출물이 항혈전 효과가 있다는 것이 한국등록특허 제512252호(특허문헌 1)에 개시되어 있고, 홍삼 분말이 주성분인 조성물에 당귀 추출물이 포함된 식품이 혈소판 응집 억제 효과가 있음이 한국공개특허 제2011-0122499호(특허문헌 2)에 개시되어 있고, 홍삼을 주성분으로 하는 조성물이 혈액순환 개선에 효과가 있음이 한국등록특허 제345040호(특허문헌 3)에 개시되어 있으며, 진피가 일부 포함된 생약 혼합물의 추출물이 동맥경화에 치료가 있음이 한국등록특허 제787174호(특허문헌 4)에 개시가 되어 있기는 하지만, 홍삼, 당귀, 진피 및 녹차 추출물이 모두 포함된 조성물이 혈관 질환에 치료 효과가 있음은 아직까지는 개시된 바가 없다. On the other hand, Korean Patent Registration No. 512252 (Patent Document 1) discloses that the methanol extract of the herbal composition mixed with the dermis and red gins with respect to the herbal medicine has an anti-thrombotic effect, and the composition containing the red ginseng powder as the main component It is disclosed in Korean Patent Publication No. 2011-0122499 (Patent Document 2) that a food containing Angelica gigantosa extract has an effect of inhibiting platelet aggregation, and it is known that a composition containing red ginseng as an active ingredient is effective in improving blood circulation. Japanese Patent No. 345040 (Patent Document 3) discloses that an extract of a crude drug mixture containing a part of a dermis has been treated in atherosclerosis in Korean Patent No. 787174 (Patent Document 4) , Angelica japonica, Dermis, and Green tea extract have therapeutic effects on vascular diseases.
따라서 본 발명자들은 혈관 질환의 예방과 치료에 효과적인 약물을 연구하던 중, 홍삼, 당귀, 진피 및 녹차의 생약 추출물이 각각의 단일 생약 추출물보다 혈관 질환의 치료에 대해 탁월한 상승 효과가 있음을 확인함으로써 본 발명을 완성할 수 있었다.Accordingly, the inventors of the present invention found that the herbal medicine extracts of red ginseng, angelica gingiva, dermis, and green tea had a superior synergistic effect on the treatment of vascular diseases than the respective herbal medicine extracts, while studying drugs effective for prevention and treatment of vascular diseases The invention could be completed.
본 발명의 목적은 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 함유하는 혈관 질환의 예방 또는 치료용 조성물을 제공하는 데에 있다.It is an object of the present invention to provide a composition for preventing or treating vascular diseases containing herbal extracts of red ginseng, Angelica gigas, dermis and green tea.
본 발명은 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 함유하는 혈관 질환의 예방 또는 치료용 조성물에 관한 것이다. 상기 혈관 질환은 동맥경화증, 고혈압, 협심증, 심근경색, 허혈성 심장질환, 심부전, 경혈관 동맥 성형술 후 발생하는 합병증, 뇌경색, 뇌출혈, 및, 뇌졸중 등으로 이루어진 군으로부터 선택된 질환일 수 있다.The present invention relates to a composition for preventing or treating vascular diseases containing herbal extracts of red ginseng, Angelica gigas, dermis and green tea. The vascular disease may be a disease selected from the group consisting of arteriosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, complications arising after cardiovascular artery arthroplasty, cerebral infarction, cerebral hemorrhage, and stroke.
본 발명의 홍삼, 당귀, 진피 및 녹차의 생약 추출물은 통상적으로 사용되는 모든 추출방법을 사용하여 제조할 수 있으며, 예컨대, 침지(냉침, 온침), 열수 추출, 초음파 추출 또는 환류 냉각 추출법을 사용할 수 있으나, 이에 한정되는 것은 아니다. 또한, 상기 홍삼, 당귀, 진피 및 녹차의 생약 추출물은 통상적인 형태의 물, 알코올 수용액, 및, 알코올 중에 선택되는 추출용매로 추출하여 제조될 수 있으며, 이러한 추출물들은 단독으로 또는 허용 가능한 생약재를 추가하여 제조될 수 있다. 상기 알코올은 탄소수 1 내지 4개로 이루어진 저급 알코올일 수 있으며, 바람직하게는 에탄올, 메탄올, 프로판올, 이소프로판올 및 부탄올 중에서 선택될 수 있다.The herbal extract of red ginseng, Angelica gigas, dermis and green tea of the present invention can be prepared by using any extraction method commonly used, and for example, immersion (cold-rolling, warming), hot water extraction, ultrasonic extraction, However, the present invention is not limited thereto. The herbal medicine extracts of red ginseng, Angelica gigas, dermis and green tea can be prepared by extracting with a conventional extraction solvent selected from among water, alcohol aqueous solution and alcohol. These extracts can be used alone or in combination with other acceptable herbal medicines . The alcohol may be a lower alcohol having 1 to 4 carbon atoms, preferably ethanol, methanol, propanol, isopropanol, and butanol.
상기 홍삼, 당귀, 진피 및 녹차의 생약 추출물은, 홍삼, 당귀, 진피 및 녹차가 2~6:1~2:1:1의 중량비율로 혼합된 생약 혼합물의 추출물일 수 있다. 바람직하게는, 상기 추출물은, 홍삼, 당귀, 진피 및 녹차가 2~6:1~2:1:1의 중량비율로 혼합된 생약 혼합물에, 상기 생약 혼합물 중량의 5∼15배의 추출용매를 가하고 40~120℃의 온도에서 2~24시간, 바람직하게는 4~12시간 동안 추출하고 이를 여과하여 얻은 여과액을 건조 및 분말화하여 제조할 수 있다. 또한 상기 추출과정을 1~3회 반복하여 추출할 수 있다. 상기 추출용매는 물, 알코올 수용액, 및, 알코올 중에서 선택되는 것일 수 있다. The herbal medicine extracts of red ginseng, Angelica gigas, dandelion, and green tea may be an extract of a herbal medicine mixture in which the red ginseng, Angelica gigas, dermis, and green tea are mixed at a weight ratio of 2: 6: 1 to 2: 1: 1. Preferably, the extract is prepared by adding an extracting solvent of 5 to 15 times the weight of the herbal mixture to a herbal mixture mixed with a weight ratio of 2: 6: 1 to 2: 1: 1 of red ginseng, Angelica jezoensis, And the mixture is extracted at a temperature of 40 to 120 ° C for 2 to 24 hours, preferably 4 to 12 hours, filtered, and dried and pulverized to obtain a filtrate. In addition, the extraction process can be repeated one to three times. The extraction solvent may be selected from water, an aqueous solution of an alcohol, and an alcohol.
상기, 본 발명의 추출물의 건조는 감압건조, 분무건조, 또는 동결건조 등의 통상적인 건조 방법을 이용하여 수행할 수 있다. The extract of the present invention can be dried using conventional drying methods such as vacuum drying, spray drying, or freeze drying.
따라서, 바람직하게는, 본 발명의 추출물은, Therefore, preferably, the extract of the present invention contains
(1공정) 홍삼, 당귀, 진피 및 녹차가 2~6:1~2:1:1의 중량비율로 혼합된 생약 혼합물에, 상기 생약 혼합물 중량의 5∼15배의 추출용매를 가하는 단계;(1 step) adding an extracting solvent of 5 to 15 times the weight of the herbal mixture to the herbal mixture mixed with the weight ratio of 2: 6: 1 to 2: 1: 1 of red ginseng, Angelica jezoensis, dermis and green tea;
(2공정) 상기 생약 혼합물과 추출용매의 혼합물을 40~120℃의 온도에서 2~24시간 동안 추출하고 여과하여 여과액을 얻는 단계; 및, (Step 2) Extracting the mixture of the crude drug mixture and the extraction solvent at a temperature of 40 to 120 ° C for 2 to 24 hours and filtering to obtain a filtrate; And
(3공정) 상기 여과액을 건조 및 분말화하는 단계;를 포함하여 제조될 수 있다. (Step 3) Drying and pulverizing the filtrate.
한편, 상기 2공정에서 여과액을 제거한 고형물에 1공정에서 이용한 추출용매를 동량으로 가한 후, 다시 2공정의 추출 및 여과 과정을 반복한 후, 3공정을 수행할 수 있다. 상기 추출 및 여과 과정은 1~3회 반복할 수 있다. Meanwhile, the extraction solvent used in the first step may be added in the same amount to the solid material from which the filtrate is removed in the above two steps, and then the extraction and filtration steps of the two steps may be repeated, followed by the third step. The extraction and filtration may be repeated one to three times.
본 발명에 따른 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 유효성분으로 함유하는 혈관 질환의 예방 또는 치료용 조성물 내의 유효성분으로서의 추출물 함량은 사용 형태 및 목적, 환자의 중증도 등에 따라 적절히 조절할 수 있으며, 고형분의 중량 기준으로 0.01~99.9 중량%, 바람직하게는 0.1~50 중량%일 수 있으나, 이에 한정되지 않는다.The content of the extract as an active ingredient in the composition for preventing or treating vascular diseases containing the herbal medicine extract of red ginseng, angelica, dermis, and green tea according to the present invention can be appropriately controlled according to the use form and purpose, the severity of the patient, May be 0.01 to 99.9% by weight, preferably 0.1 to 50% by weight, based on the weight of the solid content, but is not limited thereto.
또한 상기의 조성물은 실제 임상투여 시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있으며, 제제화 할 경우에는 보통 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용할 수 있다. 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 홍삼, 당귀, 진피 및 녹차의 추출물 및 상기 추출물의 특정 용매 가용 추출물에 적어도 하나 이상의 부형제, 예컨대, 전분, 셀락토오스, 탄산칼슘, 크로스포비돈, 경질무수규산, 유당, 스테아린산 마그네슘, 탈크, 효소처리스테비아, 미결정 셀룰로오스, 마그네슘 스테아레이트, 젤라틴 등을 섞어 사용될 수 있다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제가 포함될 수 있다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.In addition, the above composition may be administered in various formulations of oral and parenteral administration in actual clinical administration. In the case of formulation, a diluent or excipient such as a filler, a weight agent, a binder, a wetting agent, a disintegrant, Can be used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as, for example, , Starch, celluloses, calcium carbonate, crospovidone, light silicic anhydride, lactose, magnesium stearate, talc, enzyme-treated stevia, microcrystalline cellulose, magnesium stearate, gelatin and the like. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, and freeze-drying agents. Examples of the non-aqueous solvent and suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
본 발명의 추출물을 함유하는 조성물의 투여 용량은 환자의 체충, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도에 따라 달라질 수 있으며, 의사 또는 약사의 판단에 따라 일정 시간 간격으로 1일 1회~수회로 분할 투여할 수도 있다. 예컨대, 유효성분 함량 기준으로 1일 투여량이 0.001~500㎎/㎏, 바람직하게는 0.1~200㎎/㎏일 수 있다.The dose of the composition containing the extract of the present invention may be varied depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease, It may be administered once to several times a day at a predetermined time interval. For example, the daily dose may be 0.001 to 500 mg / kg, preferably 0.1 to 200 mg / kg, based on the active ingredient.
또 다른 측면에 있어서, 본 발명은 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 함유하는 혈관 질환의 예방 또는 개선용 건강기능성식품을 제공한다. 상기 건강기능성식품은 각종 식품, 음료, 식품 첨가물 등일 수 있다.In another aspect, the present invention provides a health functional food for preventing or improving vascular diseases containing herbal extracts of red ginseng, Angelica gigas, dermis, and green tea. The health functional food may be various foods, beverages, food additives, and the like.
상기 건강 기능성 식품에 함유된 유효성분으로서의 추출물의 함량은 식품의 형태, 사용하고자 하는 용도에 따라 적절하게 함유될 수 있으며, 예컨대, 전체 식품 중량의 0.01~50 중량%로 가할 수 있으며, 바람직하게는 0.1~10 중량%의 비율로 가할 수 있다. 또한 건강음료 조성물은 100㎖을 기준으로 0.02~10g, 바람직하게는 0.1~5g의 비율로 가할 수 있다. The content of the extract as an active ingredient contained in the health functional food may be appropriately determined depending on the form of the food and the intended use, and may be, for example, 0.01 to 50% by weight of the total food weight, 0.1 to 10% by weight. The health drink composition may be added at a ratio of 0.02 to 10 g, preferably 0.1 to 5 g, based on 100 ml.
본 발명의 건강음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖당 일반적으로 1~20g, 바람직하게는 5~12g이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates such as ordinary beverages as an additional ingredient, as long as it contains the extract as an essential ingredient at the indicated ratio, and there is no particular limitation to the liquid ingredient. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose, polysaccharides such as maltose, sucrose and the like, such as dextrin, cyclodextrin and the like And sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above . The ratio of the natural carbohydrate is generally 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.001~20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0.001 to 20 parts by weight per 100 parts by weight of the composition of the present invention.
특히, 본 발명의 추출물의 원료인 홍삼, 당귀, 진피 및 녹차는 예로부터 한방에서 사용되어 왔던 한약재로 인체에 투여할 경우 다른 합성 의약품에 비해 부작용의 염려가 없을 것으로 사료되며, 동물 실험을 통해 실제로 규격화된 생약 조성물에 대한 독성 시험 결과 생체내 아무런 영향이 없는 것으로 판명되었다. In particular, red ginseng, Angelica gigas, dandruff and green tea, which are raw materials for the extract of the present invention, have been used in herbal medicine for a long time. When administered to human body, there is no worry about side effects compared with other synthetic drugs. The toxicity test for standardized herbal composition was found to have no effect in vivo.
상술한 바와 같이 홍삼, 당귀, 진피 및 녹차의 생약 추출물은 혈소판 응집 억제 효과가 우수하여 동맥경화증, 고혈압, 협심증, 심근경색, 허혈성 심장질환, 심부전, 경혈관 동맥 성형술 후 발생하는 합병증, 뇌경색, 뇌출혈, 및, 뇌졸중 등을 비롯한 혈관 질환을 효과적으로 예방 또는 억제할 수 있는 조성물로 유용하게 사용될 수 있다.As described above, herbal medicine extracts of red ginseng, Angelica gigas, dermis, and green tea are excellent in the platelet aggregation inhibitory effect and can be used for the treatment of arteriosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, complications following cerebral angioplasty, , And stroke, and the like can be effectively used as a composition capable of effectively preventing or suppressing vascular diseases.
도 1은 본 발명의 실시예 1에 개시된 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 제조하는 방법을 나타낸 순서도이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flowchart showing a method for preparing herbal medicine extracts of red ginseng, Angelica gigas, dermis and green tea disclosed in Example 1 of the present invention.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해질 수 있도록 그리고 당업자에게 본 발명의 사상이 충분히 전달될 수 있도록 하기 위해 제공되는 것이다. Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the concept of the invention to those skilled in the art.
<< 실시예Example 1. 홍삼, 당귀, 진피 및 녹차 추출물의 제조> 1. Preparation of red ginseng, Angelica gigas, dermis and green tea extract>
홍삼, 당귀, 진피 및 녹차를 하기 표 1의 조건으로 혼합하고, 상기 혼합물 총 1200g에 30% 에탄올 수용액 12ℓ를 가하고 90∼95℃에서 4시간 동안 2회 추출한 후, 이를 여과 및 동결건조하고 분말화하여, 홍삼, 당귀, 진피 및 녹차의 혼합 추출물을 얻었다. Red ginseng, Angelica japonica, Dermis, and Green tea were mixed under the conditions shown in Table 1, and 12 g of a 30% aqueous ethanol solution was added to 1200 g of the mixture. The mixture was extracted twice at 90 to 95 ° C for 4 hours, To obtain a mixed extract of red ginseng, Angelica gigas, dermis and green tea.
<< 실시예Example 2. 홍삼, 당귀, 진피 및 녹차 추출물의 제조 ②> 2. Preparation of red ginseng, angelica, dermis and green tea extract ②>
2-1. 100% 에탄올 이용2-1. Using 100% Ethanol
상기 실시예 1-4와 동일하게 홍삼, 당귀, 진피 및 녹차의 각각의 추출물의 혼합물을 제조하되, 100% 에탄올을 이용하여 추출물을 제조하였다. A mixture of each of the extracts of red ginseng, Angelica gigas, dermis, and green tea was prepared in the same manner as in Example 1-4, but the extract was prepared using 100% ethanol.
2-2. 물 이용2-2. Water use
상기 실시예 1-4와 동일하게 홍삼, 당귀, 진피 및 녹차의 각각의 추출물의 혼합물을 제조하되, 물을 이용하여 추출물을 제조하였다. As in Example 1-4, a mixture of the respective extracts of red ginseng, Angelica gigas, dermis, and green tea was prepared, and water was used to prepare an extract.
<< 비교예Comparative Example 1. 비교대상 홍삼, 당귀, 진피 및 녹차 추출물의 제조 ①> 1. Comparison of red ginseng, angelica, dermis and green tea extracts ①>
상기 실시예 1의 조건과 동일하게 홍삼, 당귀, 진피 및 녹차 혼합물의 추출물을 제조하되, 하기 표 2의 조건으로 각각의 추출물을 혼합하였다. The extracts of red ginseng, Angelica gigas, dermis and green tea mixture were prepared in the same manner as in Example 1, except that the respective extracts were mixed under the conditions shown in Table 2 below.
<< 실험예Experimental Example 1. 추출물의 혈소판 응집억제 효과 확인> 1. Identification of the inhibitory effect of the extract on platelet aggregation>
1-1. 실험원리1-1. Principle of experiment
토끼로부터 혈장을 추출하여 세척 혈소판(WP, washed platelets)을 Son D.J. et al.(비특허문헌 19)을 참고하여 약간의 수정방법으로 조제하였다. 아고니스트(agonist : inducer)는 콜라겐(collagen; Chronolog Co. USA #385)을 이용하였고, 혈소판 응집 억제능은 Born G.V. et al.(비특허문헌 20)을 참고하여, 혈소판 응집 측정 장치(platelet aggregometer, ChronoLog Co. USA)를 사용한 탁도 측정 방법(turbidity method)으로 측정하였다.Plasma was extracted from the rabbits and washed platelets (WP, Wash. et al. (Non-Patent Document 19). Agonist (inducer) was collagen (Chronolog Co. USA # 385) and platelet aggregation inhibition was measured by Born G.V. was measured by turbidity method using a platelet aggregometer (ChronoLog Co. USA) according to the method described in Non-Patent Document 20.
1-2. 혈소판 풍부혈장(1-2. Platelet rich plasma ( plateletplatelet richrich plasmaplasma )의 제조)
토끼의 귀 동맥에서 항응고제인 3.8%(w/v) 구연산나트륨(sodium citrate) 5 ㎖을 넣은 튜브를 이용하여 혈액 45㎖을 채혈하였다(구연산나트륨:혈액 = 1:9, v/v). 혈소판 풍부혈장(PRP; platelet rich plasma)은 채혈한 전혈을 상온에서 120×g로 10분 동안 원심분리기(Vision Co., Korea)로 분리하여 상층액에서 얻었다.45 ml of blood was collected from the ear artery of rabbits using a tube containing 5% of 3.8% (w / v) sodium citrate as an anticoagulant (sodium citrate: blood = 1: 9, v / v). Platelet rich plasma (PRP) was obtained from the supernatant by centrifugation (Vision Co., Korea) for 10 minutes at 120 × g at room temperature.
1-3. 토끼 세척 혈소판(1-3. Rabbit wash platelets ( rabbitrabbit washedwashed plateletplatelet )의 제조)
혈소판 풍부혈장을 300×g에서 10분 동안 원심 분리하여 얻은 침전물을 2mM EDTA(ethylene diamine tetraacetic acid)를 포함한 세척용 버퍼(washing buffer : 129mM NaCl, 0.8mM KH2PO4, 8.9mM NaHCO3, 2.8mM KCl, 0.8mM MgCl2, 5.6mM glucose, 10mM HEPES, pH 7.4)로 세척하였다. 이 후, 상기 세척된 침전물을 0.35% BSA(bovine serum albumin)가 함유된 타이로이드 버퍼(modified Tyrode's buffer : 129mM NaCl, 0.8mM KH2PO4, 8.9mM NaHCO3, 2.8mM KCl, 0.8mM MgCl2, 5.6mM glucose, 10mM HEPES, pH 7.4)에 조심스럽게 재현탁시켰다. 혈소판 수는 코울터 카운터(Coulter Counter, Coulter Electronics, Hialeah, FL, USA)를 이용하여 4×108세포/㎖로 조정하였다.The platelet-rich plasma was centrifuged at 300 × g for 10 min and the precipitate was washed twice with 2 mM EDTA (ethylene diamine tetraacetic acid) in a washing buffer (129 mM NaCl, 0.8 mM KH 2 PO 4 , 8.9 mM NaHCO 3 , 2.8 washed with mM KCl, 0.8mM MgCl 2, 5.6mM glucose, 10mM HEPES, pH 7.4). Thereafter, the washed precipitate was washed with 0.35% bovine serum albumin-containing Tyrode's buffer (129 mM NaCl, 0.8 mM KH 2 PO 4 , 8.9 mM NaHCO 3 , 2.8 mM KCl, 0.8 mM MgCl 2 , 5.6 mM glucose, 10 mM HEPES, pH 7.4). Platelet counts were adjusted to 4 x 10 8 cells / ml using a Coulter Counter (Coulter Electronics, Hialeah, FL, USA).
1-4. 혈소판 응집 측정1-4. Platelet aggregation measurement
토끼 세척 혈소판 247.5㎕를 취하여 CaCl2 1mM을 첨가하고 1,000rpm에서 교반하면서 37℃로 반응(incubation)시킨 후 2분이 경과된 후 실시예 및 비교예의 생약 추출물을 10㎎/㎖의 농도로 DMSO(dimethyl sulfoxide, DMSO는 최종 농도가 0.1% 이하가 되게 함)에 녹인 샘플 2.5㎕를 처리하였고, 3분이 경과된 후에 아고니스트인 콜라겐을 투여하여 혈소판 응집을 유도하였다. 혈소판 활성화 억제 작용은 콜라겐으로 유도된 응집(%)을 대조군(A:control aggregation)으로, 각 생약 추출물을 전처리한 후 유도된 응집(%)을 샘플군(B:sample aggregation)으로 하여 하기 계산식에 따라 억제백분률(inhibition, %)로 나타내었다.247.5 토 of rabbit-washed platelets were added, and 1 mM CaCl 2 was added. After incubation at 37 캜 with stirring at 1,000 rpm, the herbal medicine extracts of Examples and Comparative Examples were dissolved in DMSO (dimethyl sulfoxide, and DMSO to a final concentration of 0.1% or less), and after 3 minutes elapsed, agonist collagen was administered to induce platelet aggregation. Platelet activation inhibition was determined by using collagen-induced aggregation (%) as a control group (A) and pretreatment of each herb extract to induce aggregation (%) as a sample aggregation The percent inhibition was expressed as inhibition (%).
A: control aggregation (%)A: control aggregation (%)
B: sample aggregation (%)B: sample aggregation (%)
1-5. 혈소판 응집 측정 결과1-5. Platelet aggregation measurement result
상기 각 시료의 혈소판 응집을 측정한 결과는 하기 표 3과 같다. The results of measurement of the platelet aggregation of the respective samples are shown in Table 3 below.
<< 실험예Experimental Example 2 : 독성실험> 2: Toxicity test>
2-1. 2-1. 급성독성Acute toxicity
본 발명의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 단기간에 과량을 섭취하였을 때 급성적(24시간 이내)으로 동물체내에 미치는 독성을 조사하고, 치사율을 결정하기 위하여 본 실험을 수행하였다. 일반적인 마우스인 ICR 마우스 계통 20마리를 대조군과 실험군에 각각 10마리씩 배정하였다. 대조군에는 PEG-400/tween-80/에탄올(8/1/1, v/v/v) 만을 투여하고, 실험군은 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 상기 PEG-400/tween-80/에탄올(8/1/1, v/v/v)에 녹여 2g/㎏/day의 농도로 각각 경구투여하였다. 투여 24시간 후에 각각의 치사율을 조사한 결과, 대조군과 2g/㎏/day 농도의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 투여한 실험군에서 마우스가 모두 생존하는 것으로 확인되었다.This experiment was conducted to investigate the toxicity of the herbal extracts of red ginseng, angelica gingiva, dermis, and green tea of the present invention to an animal body in an acute (within 24 hours) when an excessive amount of herbal extracts were taken in a short period of time and to determine the mortality rate. Twenty ICR mice were injected into each of the control and experimental groups. In the control group, only the PEG-400 / tween-80 / ethanol (8/1/1, v / v / v) was administered and the herbal extracts of red ginseng, Were dissolved in 400 / tween-80 / ethanol (8/1/1, v / v / v) and orally administered at a concentration of 2 g / kg / day. After 24 hours of administration, the mice were found to survive in the control group and in the experimental group administered with herbal extracts of red ginseng, Angelica gigas, dermis and green tea at a concentration of 2 g / kg / day.
2-2. 2-2. 실험군Experimental group 및 대조군의 장기 및 조직 독성 실험 And control organ organs and tissue toxicity experiments
장기 독성 실험은 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 각 농도로(최종농도 2g/㎏/day) 8주 동안 C57BL/6J 마우스(각 군당 10마리)에 투여하여 실험하였다. For the long-term toxicity test, the herbal extracts of red ginseng, Angelica gigas, dandruff and green tea of Example 1-4 were administered to C57BL / 6J mice (10 per group) for 8 weeks at each concentration (final concentration 2g / Respectively.
동물의 각 장기(조직)에 미치는 영향을 조사하기 위하여 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 투여한 실험군과 PEG-400/tween-80/에탄올(8/1/1, v/v/v)만을 투여한 대조군의 동물들로부터 8주 후 혈액을 채취하여 GPT(glutamate-pyruvate transferase) 및 BUN(blood urea nitrogen)의 혈액 내 농도를 Select E(Vital Scientific NV, Netherland) 기기를 이용하여 측정하였다. 그 결과, 간독성과 관계있는 것으로 알려진 GPT와 신장독성과 관계있는 것으로 알려진 BUN의 경우, 대조군과 비교하여 실험군은 별다른 차이를 보이지 않았다. 또한, 각 동물로부터 간과 신장을 정취하여 통상적인 조직절편 제작과정을 거쳐 광학현미경으로 조직학적 관찰을 시행하였으며 모든 조직에서 특이한 이상이 관찰되지 않았다. In order to investigate the effects on the organs (tissues) of animals, the experimental group in which the herbal extracts of red ginseng, Angelica gigas, dermis and green tea of Example 1-4 were administered and PEG-400 / tween-80 / ethanol (8/1/1 (Vital Scientific NV, Netherland) were used to determine the concentration of glutamate-pyruvate transferase (GPT) and blood urea nitrogen (BUN) in the blood after 8 weeks from the control group, Were measured using the instrument. As a result, GPT, which is known to be related to hepatotoxicity, and BUN, which is known to be related to renal toxicity, showed no significant difference compared to the control group. In addition, liver and kidney were sampled from each animal, and histological observation was performed with an optical microscope through a conventional tissue section production process. No abnormalities were observed in all tissues.
<< 제제예Formulation example 1 : 약학적 제제> 1: Pharmaceutical preparations>
1-1. 정제의 제조1-1. Manufacture of tablets
실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물 200g을 락토오스 175.9g, 감자전분 180g 및 콜로이드성 규산 32g과 혼합하였다. 이 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄해서 14 메쉬체를 통과시켰다. 이것을 건조시키고 여기에 감자전분 160g, 활석 50g 및 스테아린산 마그네슘 5g을 첨가해서 얻은 혼합물을 정제로 만들었다. 200 g of herbal extracts of red ginseng, Angelica gigas, dandelion and green tea of Example 1-4 were mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicic acid. To this mixture was added a 10% gelatin solution, which was pulverized and passed through a 14-mesh sieve. This was dried, and a mixture obtained by adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate was made into tablets.
1-2. 주사액제의 제조1-2. Injection preparation
실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물 1g, 염화나트륨 0.6g 및 아스코르브산 0.1g을 증류수에 용해시켜서 100㎖를 만들었다. 이 용액을 병에 넣고 20℃에서 30분간 가열하여 멸균시켰다.1 g of herbal medicine extracts of red ginseng, Angelica gigas, dermis and green tea of Example 1-4, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 ml. This solution was placed in a bottle and sterilized by heating at 20 DEG C for 30 minutes.
<< 제제예Formulation example 2 : 식품 제조> 2: Food manufacturing>
2-1. 조리용 양념의 제조2-1. Manufacture of cooking seasonings
본 발명의 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 조리용 양념에 1 중량%로 첨가하여 건강 증진용 조리용 양념을 제조하였다.The herbal extracts of red ginseng, Angelica gigas, dermis, and green tea of Example 1-4 of the present invention were added to the cooking seasoning at 1% by weight to prepare health-enhancing cooking seasonings.
2-2. 밀가루 식품의 제조2-2. Manufacture of flour food products
본 발명의 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 밀가루에 0.1 중량%로 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.Bread, cake, cookies, crackers and noodles were prepared by adding 0.1% by weight of herbal medicine extract of red ginseng, Angelica gigas, dandelion and green tea of Example 1-4 of the present invention to wheat flour, .
2-3. 2-3. 스프soup 및 육즙( And juicy ( graviesgravies )의 제조)
본 발명의 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 스프 및 육즙에 0.1 중량%로 첨가하여 건강 증진용 수프 및 육즙을 제조하였다.Health enhancing soup and juice were prepared by adding herbal extracts of red ginseng, Angelica gigas, dermis and green tea of Example 1-4 of the present invention to soup and juice at 0.1 wt%.
2-4. 유제품(2-4. dairy product( dairydairy productsproducts )의 제조)
본 발명의 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물을 우유에 0.1 중량%로 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.The herbal extracts of red ginseng, Angelica gigas, dermis and green tea of Example 1-4 of the present invention were added to milk in an amount of 0.1% by weight and various dairy products such as butter and ice cream were prepared using the milk.
2-5. 2-5. 야채주스Vegetable juice 제조 Produce
본 발명의 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물 0.5g을 토마토 주스 또는 당근주스 1,000㎖에 가하여 건강 증진용 야채주스를 제조하였다.0.5 g of herbal medicine extracts of red ginseng, Angelica gigas, dermis and green tea of Example 1-4 of the present invention were added to 1,000 ml of tomato juice or carrot juice to prepare vegetable juice for health promotion.
2-6. 2-6. 과일주스Fruit juice 제조 Produce
본 발명의 실시예 1-4의 홍삼, 당귀, 진피 및 녹차의 생약 추출물 0.1g을 사과주스 또는 포도주스 1,000㎖에 가하여 건강 증진용 과일주스를 제조하였다.Health enhancing fruit juice was prepared by adding 0.1 g of herbal medicine extract of red ginseng, Angelica gigas, dermis and green tea of Example 1-4 of the present invention to 1,000 ml of apple juice or grape juice.
Claims (9)
상기 홍삼, 당귀, 진피 및 녹차의 생약 추출물은, 홍삼, 당귀, 진피 및 녹차가 2~6:1~2:1:1의 중량비율로 혼합된 생약 혼합물의 추출물인 것을 특징으로 하는 동맥경화증, 협심증, 심근경색, 허혈성 심장질환, 뇌경색, 및, 뇌졸중에서 선택되는 혈관 질환의 예방 또는 치료용 조성물.The method according to claim 1,
The herbal medicine extract of red ginseng, Angelica giganteus, dermis, and green tea is an extract of a herbal medicine mixture wherein red ginseng, Angelica gigas, dermis and green tea are mixed at a weight ratio of 2: 6: 1 to 2: 1: 1. Angina pectoris, myocardial infarction, ischemic heart disease, cerebral infarction, and stroke.
상기 홍삼, 당귀, 진피 및 녹차의 생약 추출물은, 물, 알코올 수용액, 및, 알코올 중에 선택되는 추출용매로 추출되는 것을 특징으로 하는 동맥경화증, 협심증, 심근경색, 허혈성 심장질환, 뇌경색, 및, 뇌졸중에서 선택되는 혈관 질환의 예방 또는 치료용 조성물.3. The method according to claim 1 or 2,
Wherein the herbal medicine extracts of red ginseng, Angelica gigas, dermis, and green tea are extracted with an extraction solvent selected from among water, an aqueous alcohol solution, and alcohol, which is selected from the group consisting of arteriosclerosis, angina pectoris, myocardial infarction, ischemic heart disease, Or a pharmaceutically acceptable salt thereof.
상기 홍삼, 당귀, 진피 및 녹차의 생약 추출물은, 홍삼, 당귀, 진피 및 녹차가 2~6:1~2:1:1의 중량비율로 혼합된 생약 혼합물의 추출물인 것을 특징으로 하는 동맥경화증, 협심증, 심근경색, 허혈성 심장질환, 뇌경색, 및, 뇌졸중에서 선택되는 혈관 질환의 예방 또는 개선용 건강기능식품.6. The method of claim 5,
The herbal medicine extract of red ginseng, Angelica giganteus, dermis, and green tea is an extract of a herbal medicine mixture wherein red ginseng, Angelica gigas, dermis and green tea are mixed at a weight ratio of 2: 6: 1 to 2: 1: 1. A health functional food for preventing or ameliorating a vascular disease selected from angina pectoris, myocardial infarction, ischemic heart disease, cerebral infarction, and stroke.
상기 홍삼, 당귀, 진피 및 녹차의 생약 추출물은, 물, 알코올 수용액, 및, 알코올 중에 선택되는 추출용매로 추출되는 것을 특징으로 하는 동맥경화증, 협심증, 심근경색, 허혈성 심장질환, 뇌경색, 및, 뇌졸중에서 선택되는 혈관 질환의 예방 또는 개선용 건강기능식품.The method according to claim 5 or 6,
Wherein the herbal medicine extracts of red ginseng, Angelica gigas, dermis, and green tea are extracted with an extraction solvent selected from among water, an aqueous alcohol solution, and alcohol, which is selected from the group consisting of arteriosclerosis, angina pectoris, myocardial infarction, ischemic heart disease, ≪ / RTI > or a pharmaceutically acceptable salt thereof.
(2공정) 상기 생약 혼합물과 추출용매의 혼합물을 40~120℃의 온도에서 2~24시간 동안 추출하고 여과하여 여과액을 얻는 단계; 및,
(3공정) 상기 여과액을 건조 및 분말화하는 단계;를 포함하는 것을 특징으로 하는 홍삼, 당귀, 진피 및 녹차의 생약 추출물의 제조방법.(1 step) adding an extracting solvent of 5 to 15 times the weight of the herbal mixture to the herbal mixture mixed with the weight ratio of 2: 6: 1 to 2: 1: 1 of red ginseng, Angelica jezoensis, dermis and green tea;
(Step 2) Extracting the mixture of the crude drug mixture and the extraction solvent at a temperature of 40 to 120 ° C for 2 to 24 hours and filtering to obtain a filtrate; And
(Step 3) A step of drying and pulverizing the filtrate. The method for producing a herbal extract of red ginseng, Angelica gigas, dermis and green tea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120019860A KR101392204B1 (en) | 2012-02-27 | 2012-02-27 | Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120019860A KR101392204B1 (en) | 2012-02-27 | 2012-02-27 | Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130098051A KR20130098051A (en) | 2013-09-04 |
| KR101392204B1 true KR101392204B1 (en) | 2014-05-08 |
Family
ID=49450138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120019860A KR101392204B1 (en) | 2012-02-27 | 2012-02-27 | Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101392204B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160141986A (en) | 2015-06-02 | 2016-12-12 | 재단법인 진안홍삼연구소 | A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease |
| KR20210133073A (en) | 2020-04-28 | 2021-11-05 | 임순애 | Preparation method for Angelica gigas root |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150034014A (en) * | 2013-09-25 | 2015-04-02 | 엘지전자 주식회사 | Antimicrobial composition comprising ginseng extract and green tea extract, antimicrobial filter and method for manufacturing the same |
| CN104435504A (en) * | 2014-12-19 | 2015-03-25 | 李爱花 | Traditional Chinese medicine liquid for treating heart failure and preparation method |
| CN104771601B (en) * | 2015-04-14 | 2018-06-19 | 张坤镛 | A kind of combination agent for improving blood viscosity and hematoblastic aggregation |
| CN104922445B (en) * | 2015-07-10 | 2018-08-28 | 江苏省中医院 | A kind of Traditional Chinese medicine compound composition and the preparation method and application thereof with treatment heart failure effect |
| CN106819217A (en) * | 2016-12-22 | 2017-06-13 | 广州肇基生物科技有限公司 | The health protection tea of blood can be improved |
| CN107007710B (en) * | 2017-04-27 | 2020-12-29 | 上海市浦东新区浦南医院 | Recovery and consciousness restoring granular preparation and preparation method and application thereof |
| KR102496867B1 (en) * | 2020-02-12 | 2023-02-07 | 대한민국 | Composition having preventive or therapeutic effect on vascular restenosis, pharmaceutical composition including the composition |
-
2012
- 2012-02-27 KR KR1020120019860A patent/KR101392204B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160141986A (en) | 2015-06-02 | 2016-12-12 | 재단법인 진안홍삼연구소 | A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease |
| KR20210133073A (en) | 2020-04-28 | 2021-11-05 | 임순애 | Preparation method for Angelica gigas root |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130098051A (en) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101392204B1 (en) | Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases | |
| KR100425022B1 (en) | Ginseng extract and pharmaceutical composition containing it | |
| RU2294208C2 (en) | Using treated ginseng extract and saponins isolated from its | |
| KR100522579B1 (en) | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress | |
| KR101225566B1 (en) | Functional food composition for relieving menopausal symptom | |
| KR20180016275A (en) | Food composition and Pharmaceutical composition for activation of anti-oxidant, anti-inflammatory or immunity comprising hot water extract of Angelica gigas nakai, Cnidium officinale makino, Paeonia lactiflora and extract of Red ginseng or extract of Gapi taheebo | |
| KR102099147B1 (en) | Composition for preventing, ameliorating or treating obesity comprising Heracleum moellendorffii root and Torilis japonica mixed extract as effective component | |
| KR101228920B1 (en) | A composition comprising of a leaf extract of dendropanax morbifera for treating and preventing intestinal function disorder | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR20170109703A (en) | A pharmaceutical composition for preventing or treating cancer comprising fractions of herbal mixture extract | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
| KR102282839B1 (en) | Composition for relieving or improving hangover | |
| KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
| KR100471340B1 (en) | A new process for enhancing the efficacies of Ginseng | |
| KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
| KR101778227B1 (en) | Composition for anti-obesity comprising extract of Morus alba as effective component | |
| KR101367885B1 (en) | A composition comprising the extract of combined herb of Panax ginseng and Vitis genus plant treating and preventing neuro-degenerative disease and enhancing memory power | |
| KR100453542B1 (en) | Food additive and health foods containing Ginseng extract | |
| KR101497818B1 (en) | Pharmaceutical composition comprising the organic solvent fraction of achyranthis radix as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101596006B1 (en) | Composition for Prevention and Treatment of Cardiovascular Diseases | |
| KR101770600B1 (en) | Composition for enhancing blood circulation containing a lot of acidic polysaccharide in Panax ginseng by high pressure/enzyme dissolution | |
| KR100555653B1 (en) | Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety | |
| KR20140003705A (en) | Method for manufacturing red ginseng extract with enhanced function and the extact thereof | |
| KR101526066B1 (en) | Pharmaceutical composition comprising the organic solvent fraction yielded from hot water extraction of laminaria japonica as an effective component for prevention or treatment of thrombosis and health functional food comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20180416 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20191029 Year of fee payment: 6 |